2022 World-Class Speaker Faculty:

Speakers

Expand/Collapse

Abhigyan Satyam
Assistant Professor
Harvard Medical School, Harvard University

Track A - Day 1 PM

2:30 pm | Targeted Inhibition of Intracellular Complement Activation to Control Tissue Injury

Andrea Tenner
Professor
University of California, Irvine

Axel Vater
Founder & Chief Scientific Officer
APTARION biotech AG

Day Two

Thursday, September 29 2022

2:00 pm | C5a Neutralization by Clinical-Stage AON-D21 Shows Promise in Animal Models from Pneumonia to Lung Cancer

Baehyun Shin
Senior Scientist
UCB

Track A - Day 1 AM

12:30 pm | In Vitro Neuromuscular Junction Models to Functionally Dissect Anti-AChR Pathogenic Mechanism in Myasthenia Gravis

Bärbel Rohrer
Professor
Medical University of South Carolina

Track A - Day 1 AM

12:00 pm | Complement Inhibitor for the Treatment of Age-related Macular Degeneration: Target, Location of Delivery & Timing?

Cynthia A. Lemere
Associate Professor of Neurology
Brigham & Women’s Hospital & Harvard Medical School

Daniel E. Benjamin
Chief Executive Officer
Cascade Biotechnology Inc.

Day Two

Thursday, September 29 2022

3:00 pm | Targeted Delivery Platform of sC3, a Complement Depleting Protein, Using Viral Delivery, Conjugate Guidance, & Localized Application Modalities

David Heja
Senior Scientist
eGenesis

Day Two

Thursday, September 29 2022

12:30 pm | Long-Term Graft Survival Achieved in NHP Recipients of Life- Sustaining, Endogenous Retrovirus-Free, Human-Compatible (Huco™) Porcine Renal Xenografts

Dorothy Schafer
Associate Professor of Neurobiology
UMass Chan Medical School

Douangsone Vadysirisack
Translational Biology Lead
UCB

Edward F. Patz, Jr
CEO & James and Alice Chen Distinguished Professor of Radiology, Pharmacology & Cancer Biology
Grid Therapeutics, Duke University School of Medicine

Day Two

Thursday, September 29 2022

12:00 pm | Complement as a Natural Adjuvant to Promote Anti-Tumor Immunity in Cancer Therapy

Ellen Cahir-McFarland
Senior Vice President, Research
Annexon Biosciences

Track A - Day 1 PM

2:00 pm | Stop the Start: The Effect of Anti-C1q Inhibitors on Neurodegeneration

Emma Persson
Scientist, Clinical
argenx BV

Track B - Day 1 AM

12:10 pm | Safety, Efficacy, Pharmacokinetics & Pharmacodynamics of ARGX-117, a Therapeutic Antibody Targeting Complement Factor 2

Gerry Cox
Interim Chief Medical Officer, Chief Development Strategist
CANbridge Pharmaceuticals

Track B - Day 1 AM

11:40 am | A Phase 1 Study of CAN106: A Novel, Long-Acting, Anti-C5 Monoclonal Antibody in Development for Complement-Mediated Diseases

Jeffry B. Lawrence
Industry Expert
Formerly at Solid Biosciences

Day One

Wednesday, September 28 2022

9:50 am | Panel Discussion: Defining the Therapeutic Windows of Drugs to Ensure Patient Safety Whilst Maintaining Drug Efficacy

9:20 am | Complement Inhibitory Drugs: Dose Selection & Schedule for Different Indications Based Upon Disease Mechanism, Pharmacokinetics & Pharmacodynamics

Karthik Viswanathan
Executive Director, Research
Visterra, Inc.

Track A - Day 1 PM

3:00 pm | Precision Antibody-Based Therapeutics for Complement Regulation

Keith Wilcoxen
Senior Vice President, Global Research
Zenas BioPharma

Day Two

Thursday, September 29 2022

3:30 pm | Opportunities for Complement Therapy in China

Maciej Markiewski
Professor
Texas Tech University Health Sciences Center

Day Two

Thursday, September 29 2022

10:00 am | Finding Optimal Targets for Complement-Based Cancer Therapy

Madhumita Das
Director, Immunology Discovery
Apellis Pharmaceuticals

Day One

Wednesday, September 28 2022

8:40 am | Complement Industry Leaders’ Chat - 2021/22 in Review & Looking Ahead

Day Two

Thursday, September 29 2022

11:30 am | Expanding Horizons in Cancer Therapeutics Targeting the Complement Pathway

Martin J. Schmidt
Chief Scientific Officer
Kypha

Track A - Day 1 PM 2

4:31 pm | 1. Complement Biomarkers, the Utility of Complement Assays & Evaluating the Best Methods to Accurately Quantify Complement Activation

Martin Kolev
Associate Director Complement Science
Apellis Pharmaceuticals

Day Two

Thursday, September 29 2022

9:30 am | Inside-Out of Complement in Cancer Immunotherapy

Michael Schwenkert
Chief Technology Officer
Svar

Day One

Wednesday, September 28 2022

10:20 am | Importance of Complement Assays in Drug Development

Michael Storek
Head of Complement Cluster
Sanofi

Day One

Wednesday, September 28 2022

9:50 am | Panel Discussion: Defining the Therapeutic Windows of Drugs to Ensure Patient Safety Whilst Maintaining Drug Efficacy

8:40 am | Complement Industry Leaders’ Chat - 2021/22 in Review & Looking Ahead

8:30 am | Chair’s Opening Remarks

Michelle Elvington
Scientific Director - Complement & Clinical Development
Kypha

Day One

Wednesday, September 28 2022

9:10 am | Overcoming Challenges for Accurate Real World Complement Analysis

Nirmal K. Banda
Professor
University of Colorado Anschutz Medical Campus

Track A - Day 1 AM

11:30 am | Therapeutic Targeting C5AR1 to Diagnosing & Preventing Early Rheumatoid Arthritis as a New Pathway to Precision Medicine

Petra Duda
Head of Development – Zilucoplan
UCB

Track B - Day 1 PM

3:00 pm | Phase 3 Data in Generalized Myasthenia Gravis

Renfeng Guo
Chief Science Officer
InflaRx N.V.

Track B - Day 1 PM

2:00 pm | Treatment of Critically Ill COVID-19 Patients with Vilobelimab, a First-in-Class Anti-C5a Antibody

Richard Lee
Chief Medical Officer
Kira Pharma

Day One

Wednesday, September 28 2022

8:40 am | Complement Industry Leaders’ Chat - 2021/22 in Review & Looking Ahead

Ruchi Gupta
Director
Johnson & Johnson

Day One

Wednesday, September 28 2022

9:50 am | Panel Discussion: Defining the Therapeutic Windows of Drugs to Ensure Patient Safety Whilst Maintaining Drug Efficacy

Day Two

Thursday, September 29 2022

8:50 am | Chair’s Opening Remarks

Speaker to be Announced

ChemoCentryx

Stefan Wawersik
Vice President of Research
Q32 Bio Inc.

Day Two

Thursday, September 29 2022

2:30 pm | Developing Locally Targeted Complement Therapeutics

Stephen Poor
Director External Opportunities & Translational Biomarkers
Novartis Institutes for Biomedical Research

Track B - Day 1 PM

2:30 pm | An Update & Analysis of the Macular Degeneration Complement Landscape

Thomas J. Schall
President, Chief Executive Officer & Chairman of the Board
ChemoCentryx

Day Two

Thursday, September 29 2022

9:00 am | Success Stories & Lessons Learned: TAVNEOS (Avacopan) – an Oral Inhibitor of the Complement C5a Receptor for the Treatment of ANCAAssociated Vasculitis

Ulrich Thienel
Chief Executive Officer
ReAlta Life Sciences

Track B - Day 1 AM

11:30 am | RLS-0071: Dual Target Inhibition in Support of Hypoxic Ischemic Encephalopathy

Wenchao Song
Kira Scientific Founder & Chair
Kira Pharma

Track B - Day 1 PM 2

4:31 pm | 2. Overcoming Challenges with Next Generation Complement Drug Development